Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Lytgobi FDA Approved for Intrahepatic Cholangiocarcinoma with FGFR2 Fusion

JHOP - October 2022 Vol 12, No 5 - FDA Oncology Update
NEW DRUGS

On September 30, 2022, the FDA accelerated the approval of futibatinib (Lytgobi; Taiho Oncology), a tyrosine kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (CCA) and FGFR2 gene fusion or other rearrangements. Futibatinib received a breakthrough therapy designation for this indication.

This approval was based on results of the multicenter, open-label, single-arm TAS-120-101 clinical trial of 103 patients with unresectable, locally advanced, intrahepatic CCA associated with FGFR2 fusion or other rearrangements.

The primary end points were overall response rate and duration of response. All patients received 20 mg of futibatinib orally until disease progression or unacceptable adverse events. Of the 103 patients, 43 (42%) had a partial response (95% confidence interval [CI], 32-52) to futibatinib, with a median duration of response of 9.7 months (95% CI, 7.6-17.1).

The most common (≥20%) adverse events were nail problems, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, abdominal pain, dry skin, arthralgia, dysgeusia, dry eye, nausea, decreased appetite, urinary tract infection, palmar-plantar erythrodysesthesia syndrome, and vomiting.

Related Items
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pedmark First Drug Approved for Hearing Loss Prevention in Children with Solid Tumors
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imfinzi Receives New FDA Indication for Advanced or Metastatic Biliary Tract Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Nubeqa Now Indicated for Metastatic Hormone-Sensitive Prostate Cancer
JHOP - October 2022 Vol 12, No 5 published on October 24, 2022 in FDA Oncology Update
Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor
JHOP - August 2022 Vol 12, No 4 published on August 22, 2022 in FDA Oncology Update
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.